Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical...Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Our primary focus is on the orphan disease Idiopathic Intracranial Hypertension (IIH), a large and growing market opportunity with no regulatory cleared treatmentsMore